Incyte logo

Incyte Share Price (NASDAQ: INCY)

$84.84

0.84

(1%)

Last updated on

Check the interactive Incyte Stock chart to analyse performance

Incyte stock performance

as on August 28, 2025 at 1:29 am IST

  • Today's Low:$84.47
    Today's High:$85.06

    Day's Volatility :0.69%

  • 52 Weeks Low:$53.56
    52 Weeks High:$87.24

    52 Weeks Volatility :38.61%

Incyte Stock Returns

PeriodIncyte CorporationSector (Health Care)Index (Russel 2000)
3 Months
27.21%
4.2%
0.0%
6 Months
14.8%
-8.0%
0.0%
1 Year
27.99%
-12.0%
0.0%
3 Years
19.15%
7.7%
-6.9%

Incyte Corporation Key Stats

Check Incyte key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close
$84.0
Open
$84.49
Today's High
$85.06
Today's Low
$84.47
Market Capitalization
$16.6B
Today's Volume
$2.3M
52 Week High
$87.24
52 Week Low
$53.56
Revenue TTM
$4.6B
EBITDA
$1.1B
Earnings Per Share (EPS)
$4.23
PE Ratio
20.04
Profit Margin
18.99%
Quarterly Earnings Growth YOY
0.07%
Return On Equity TTM
24.3%

Stock Returns calculator for Incyte Stock including INR - Dollar returns

The Incyte stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Incyte investment value today

Current value as on today

₹1,33,935

Returns

₹33,935

(+33.94%)

Returns from Incyte Stock

₹29,250 (+29.25%)

Dollar Returns*

₹4,685 (+4.68%)

Indian investors sentiment towards Incyte Stock

117%

Period: Jul 28, 2025 to Aug 27, 2025. Change in 30 Days versus previous period

Search interest for Incyte Stock from India on INDmoney has increased by 117% in the last 30 days, reflecting an upward trend in search activity.

Indian Mutual Funds that invest in Incyte Stock

NameShares HeldChange in Shares% of Assets
Motilal Oswal S&P 500 Index Fund Direct Growth logo
1299
1.27
0.02%

Global Institutional Holdings in Incyte Corporation

  • Name

    Holdings %

  • Baker Bros Advisors LP

    15.74%

  • Vanguard Group Inc

    10.31%

  • BlackRock Inc

    8.93%

  • Dodge & Cox

    7.47%

  • State Street Corp

    5.14%

  • AQR Capital Management LLC

    4.20%

Analyst Recommendation on Incyte Stock

Rating
Trend

Buy

    55%Buy

    44%Hold

    0%Sell

Based on 29 Wall street analysts offering stock ratings for Incyte(by analysts ranked 0 to 5 stars)

Incyte Share Price Target

What analysts predicted

Downside of 4.42%

Target:

$81.09

Current:

$84.84

Incyte share price target is $81.09, a slight Downside of 4.42% compared to current price of $84.84 as per analysts' prediction.

Incyte Stock Insights

  • Price Movement

    In the last 7 days, INCY stock has moved down by -2.9%
  • Increasing Revenue

    Revenue is up for the last 2 quarters, 1.05B → 1.21B (in $), with an average increase of 13.4% per quarter
  • Increasing Net Profit

    Netprofit is up for the last 2 quarters, 158.20M → 404.99M (in $), with an average increase of 60.9% per quarter
  • INCY vs ALNY (1 yr)

    In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 60.7% return, outperforming this stock by 32.7%
  • INCY vs ALNY (3 yr)

    In the last 3 years, Alnylam Pharmaceuticals, Inc. has given 113.9% return, outperforming this stock by 96.4%
  • Price to Sales

    ForINCY every $1 of sales, investors are willing to pay $3.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $23.9 for every $1 of sales.

Incyte Corporation Financials

Revenue
Profit
Cash Flow
Annually
Quarterly
FY19
FY20
FY21
FY22
FY23
FY24
FY24Y/Y Change
Revenue
$4.2B
↑ 14.76%
Net Income
$32.6M
↓ 94.54%
Net Profit Margin
0.77%
↓ 15.4%

Incyte Technicals Summary

Sell

Neutral

Buy

Incyte is currently in a neutral trading position according to technical analysis indicators.

Incyte Corporation Vs Peers

Returns
Ratio's
Overview
Company Name1 Month6 Month1 Year3 Years5 Years
Incyte Corporation logo
19.74%
14.8%
27.99%
19.15%
-12.81%
Regeneron Pharmaceuticals, Inc. logo
5.25%
-16.41%
-51.02%
-0.89%
-5.24%
Beone Medicines Ltd logo
0.7%
10.59%
55.36%
84.02%
27.45%
Vertex Pharmaceuticals Incorporated logo
-17.38%
-18.44%
-20.97%
37.43%
38.65%
Alnylam Pharmaceuticals, Inc. logo
36.48%
90.27%
60.71%
115.82%
240.11%

About Incyte Corporation

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI (ruxolitinib) for the treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for treating relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a selective fibroblast growth factor receptor kinase inhibitor for the treatment of unresectable biliary tract cancer, metastatic cholangiocarcinoma, and myeloid/lymphoid neoplasms; ICLUSIG (ponatinib), a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma; and NIKTIMVO (axatilimab-csfr) for treating chronic graft-versus-host disease, as well as OPZELURA (ruxolitinib) cream for treating atopic dermatitis. Its clinical stage products include INCB123667 (CDK2) for ovarian cancer; INCB161734 (KRASG12D) for cancers; INCA33890 (TGFßR2xPD-1) for solid tumors; Ruxolitinib cream for mild to moderate hidradenitis suppurativa (HS); Povorcitinib for HS, nonsegmental vitiligo, prurigo nodularis, and asthma and chronic spontaneous urticaria; INCB000262 (MRGPRX2) and INCB000547 (MRGPRX4) for systemic immune and neuro-immune disorders; INCA034460 (anti-CD122) for vitiligo; and Zilurgisertib (ALK2) for fibrodysplasia ossificans progressive. It has collaboration with Genesis Therapeutics, Inc. The company sells its products to specialty and retail pharmacies, hospital pharmacies, and specialty distributors and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.
Organization
Incyte
Employees
2617
CEO
Mr. William Meury
Industry
Health Technology

Key Management of Incyte Corporation

NameTitle
Dr. Pablo J. Cagnoni M.D., Ph.D.
President and Head of Research & Development
Ms. Christiana Stamoulis M.B.A.
Executive VP & CFO
Mr. Herve Hoppenot
Advisor to CEO & Director
Dr. Steven H. Stein M.D.
Executive VP & Chief Medical Officer
Mr. William Meury
CEO, President & Director
Mr. Thomas Tray
VP of Finance, Chief Accounting Officer & Controller
Mr. Michael James Morrissey
Executive VP & Head of Global Technical Operations
Greg Shertzer
Senior Director of Investor Relations
Ms. Sheila A. Denton J.D.
Executive VP, General Counsel & Corporate Secretary
Ms. Pamela M. Murphy
Vice President of Investor Relations & Corporate Communications

Important FAQs about investing in INCY Stock from India :

What is Incyte share price today?

Incyte share price today is $84.84 as on at the close of the market. Incyte share today touched a day high of $85.06 and a low of $84.47.

What is the 52 week high and 52 week low for Incyte share?

Incyte share touched a 52 week high of $87.24 and a 52 week low of $53.56. Incyte stock price today i.e. is closed at $84.84, lower by 2.75% versus the 52 week high.

How to invest in Incyte Stock (INCY) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Incyte on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Incyte Shares that will get you 0.0177 shares as per Incyte share price of $84.84 per share as on August 28, 2025 at 1:29 am IST.

What is the minimum amount required to buy Incyte Stock (INCY) from India?

Indian investors can start investing in Incyte (INCY) shares with as little as ₹87.86 or $1 (as of August 28, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹878.60 in Incyte stock (as per the Rupee-Dollar exchange rate as on August 28, 2025). Based on Incyte share’s latest price of $84.84 as on August 28, 2025 at 1:29 am IST, you will get 0.1179 shares of Incyte. Learn more about fractional shares .

What are the returns that Incyte has given to Indian investors in the last 5 years?

Incyte stock has given -12.81% share price returns and 18.89% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?